Core Viewpoint - ST Unimed (002581.SZ) reported a significant increase in revenue for Q3, achieving 141 million yuan, which is double the total revenue of the first two quarters of the year, leading to a total revenue of 212 million yuan for the first three quarters [1] Group 1: Financial Performance - The company faced challenges in the first half of the year due to the suspension of production and sales at its subsidiary Tianjin Unimed, resulting in poor revenue and profit performance [1] - The financial performance improved in Q3, aided by the accelerated investment and consolidation of Sichuan Gukang Pharmaceutical Co., which is expected to contribute significantly to the company's overall financial results [1] - Gukang Pharmaceutical is projected to achieve revenues of 73.93 million yuan and a net profit of 4.15 million yuan in 2024, with net profit accelerating to 9.85 million yuan in the first four months of 2025, surpassing the total for 2024 [1] Group 2: Business Development - The company is focusing on sustainable development and has a robust pipeline of core products, including the nerve growth factor injection product [2] - The fully-owned subsidiary Shandong Yandu Biotechnology is developing a range of biopharmaceuticals, including a second-generation nerve growth factor eye drop, which is entering Phase III clinical trials [2] - The Chinese ophthalmic drug market is expected to grow at a compound annual growth rate of 19.1% from 2024 to 2030, indicating a significant market opportunity for the company's products [2] Group 3: Strategic Initiatives - The company is actively promoting rectification measures for Tianjin Unimed and is progressing with the construction of the Shandong Unimed Biopharmaceutical Industrial Park, which is set to commence in 2024 [3] - These initiatives are expected to enhance the company's operational performance and governance, potentially leading to continued revenue and profit recovery in the future [3]

Core Points - ST Unimed (002581.SZ) released its Q3 2025 financial report on October 29, 2025 [1] - As of October 28, 2025, six institutional investors disclosed holdings in ST Unimed A-shares, totaling 139 million shares, which represents 21.07% of the total share capital [1] - The institutional investors include Xiamen Hengxing Group Co., Ltd., Shenzhen Jialian Private Securities Investment Fund Management Co., Ltd. - Jialian No. 1 Securities Investment Fund, Shenzhen Yilian Technology Co., Ltd., Shenzhen Juyunlai Investment Partnership (Limited Partnership), Beijing Peking University Unimed Bioengineering Group Co., Ltd., and Shenwan Hongyuan Securities Co., Ltd. [1] - The total institutional holding percentage decreased by 1.31 percentage points compared to the previous quarter [1] - In terms of public funds, 13 public funds were not disclosed in this period compared to the previous quarter, including Southern CSI 1000 ETF, Huaxia CSI 1000 ETF, GF CSI 1000 ETF, Fortune CSI 1000 Index Enhanced A, and China Merchants CSI 1000 Index Enhanced A [1]

Core Viewpoint - ST Unimed (未名医药) reported a significant decline in profitability despite a revenue increase in Q3 2025, primarily due to the suspension of its core subsidiary, Tianjin Unimed, affecting its operations and stock status [1][3]. Financial Performance - In Q3 2025, ST Unimed achieved a revenue of 141 million yuan, marking a 35.94% year-on-year increase, but the cumulative revenue for the first three quarters fell by 32.62% to 212 million yuan [2][3]. - The net profit attributable to shareholders for the first three quarters was a loss of 68.81 million yuan, a drastic decline of 570.46% compared to a profit of 14.63 million yuan in the same period last year [2][3]. - The basic and diluted earnings per share were both -0.1043 yuan, reflecting a year-on-year decrease of 569.82% [2]. Operational Challenges - The operational difficulties stem from the suspension of Tianjin Unimed's production and sales since April 2025 due to regulatory compliance issues, which has severely impacted the company's revenue [3][5]. - Tianjin Unimed accounted for 60.09% of the company's total revenue in 2024, highlighting its critical role in ST Unimed's financial health [3]. Strategic Actions - ST Unimed has resolved historical equity issues with its wholly-owned subsidiary, Xiamen Unimed, by regaining 34% of its shares from Hangzhou Qiangxin Biotechnology Co., Ltd. through a settlement agreement [4]. - The company is actively seeking new growth opportunities, including a 45 million yuan investment in Sichuan Gukang Pharmaceutical Co., Ltd., acquiring a 51% stake and providing financial support of up to 55 million yuan [5].

每经AI快讯，ST未名（SZ 002581，收盘价：7.43元）10月28日晚间发布公告称，公司第六届第八次董 事会会议于2025年10月28日以通讯方式召开。会议审议了《2025年第三季度报告》等文件。 2025年1至6月份，ST未名的营业收入构成为：制药业务分部占比100.0%。 截至发稿，ST未名市值为49亿元。 每经头条（nbdtoutiao）——A股突破4000点！十年沉寂终迎爆发，科技主线重塑市场，"慢牛"新格局开 启！ （记者 王晓波） ...

一、董事会会议召开情况 证券代码：002581 证券简称：ST未名 公告编号：2025-078 山东未名生物医药股份有限公司 第六届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 表决情况：同意 11 票,反对 0 票，弃权 0 票。 表决结果：通过。 三、备查文件 1、山东未名生物医药股份有限公司第六届董事会第八次会议决议。 特此公告。 山东未名生物医药股份有限公司(以下简称"公司")第六届董事会第八次会 议于 2025 年 10 月 28 日上午 10 时以通讯方式召开。应参加表决董事 11 名，实际 参加表决董事 11 人，分别为：岳家霖、刘文俊、徐隽雄、周婷、陈星、史晓如、 黄桂源、蔡艳红、张荣富、杨军、夏阳。董事会会议通知已于 2025 年 10 月 24 日 以通讯方式发出，会议由公司董事长岳家霖先生主持。本次董事会的召集和召开 符合国家有关法律法规、《董事会议事规则》及《公司章程》的规定。本次会议 审议了如下议案： 二、董事会会议审议情况 （一）审议通过了《2025 年第三季度报告》 董事会认为，公司《2025 年第三 ...

山东未名生物医药股份有限公司 2025 年第三季度报告 证券代码：002581 证券简称：ST 未名 公告编号：2025-077 山东未名生物医药股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示： 1.董事会及董事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个 别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完 整。 3.第三季度财务会计报告是否经过审计 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 141,278,412.80 | 35.94% | 212,049,953.68 | -32.62% | | 归属于上市公司股东 | ...

证券代码：002581 证券简称：ST 未名 公告编号：2025-076 山东未名生物医药股份有限公司 关于 2025 年股票期权激励计划授予完成的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、期权简称：未名 JLC3 2、期权代码：037929 3、授予日：2025 年 9 月 16 日 4、授予登记完成日：2025 年 10 月 24 日 5、行权价格：7.39 元/股 6、授予数量：45,981,400 份 7、授予登记人数：148 人 8、期权有效期：44 个月 9、授予行权期：本次授予的激励对象行权期为 2 期，分别为自授予日起 20 个月后、32 个月后分两次行权。 山东未名生物医药股份有限公司（以下简称"公司"）根据中国证监会《上 市公司股权激励管理办法》（以下简称"《管理办法》"）、深圳证券交易所和 中国证券登记结算有限责任公司深圳分公司有关规则的规定及公司 2025 年第二 次临时股东会的授权，依据公司召开的 2025 年第二次临时股东会审议通过的《山 东未名生物医药股份有限公司 2025 年股票期权激励计划（草 ...

Group 1: New Stock Issuances - Cash option declaration period for *ST Tianmao (000627) is from September 15 to September 19, 2025[1] - *ST Zitian (300280) has 11 trading days remaining until the last trading day during the delisting arrangement period[1] - *ST Dongtong (300379) has reported severe abnormal fluctuations in stock price[1] Group 2: Market Alerts - Jiushi Media (601929) has experienced significant abnormal fluctuations in stock price[1] - Xian Dao Intelligent (300450) has reported severe abnormal fluctuations in stock price[1] - Hangke Technology (688006) has issued a notice regarding stock performance[1] Group 3: Trading Notifications - Shanghai Construction (600170) has issued a trading notification on September 18, 2025[1] - Junsheng Electronics (600699) has issued a trading notification on September 18, 2025[1] - ST Changyuan (600525) has issued a trading notification on September 18, 2025[1]

New Stock Issuance - Cash option declaration period for *ST Tianmao (000627) is from September 15 to September 19, 2025[1] - *ST Zitian (300280) has 12 trading days remaining until the last trading day during the delisting arrangement period[1] Trading Alerts - *ST Jishi Media (601929) reported severe abnormal fluctuations in stock price[1] - *ST Yushun (002289) and *ST Weier (002058) are under scrutiny due to abnormal trading activities[1] Company Announcements - *ST Gao Hong (000851) and *ST Dongtong (300379) have recent announcements regarding their financial status[1] - Shanghai Construction (600170) and Zhongke Shuguang (603019) have disclosed important updates on their operations[1] Market Trends - The report indicates a trend of increased scrutiny on companies with abnormal trading patterns, reflecting a tightening regulatory environment[2] - The number of companies under cash option declarations and delisting arrangements suggests a potential increase in market volatility[1]

证券代码：002581 证券简称：ST未名 公告编号：2025-071 山东未名生物医药股份有限公司 2025 年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚 假记载、误导性陈述或重大遗漏。 特别提示 1. 本次股东会未出现否决议案的情形； 2. 本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开情况 1. 会议召开时间： （1）现场会议召开时间：2025 年 9 月 16 日下午 2:30 （2）网络投票时间： ①通过深圳证券交易所交易系统进行投票的时间：2025 年 9 月 16 日上午 9:15-9:25，9:30-11:30，下午 1:00-3:00； ②通过互联网投票系统进行网络投票的时间：2025 年 9 月 16 日 9:15-15:00。 2. 现场会议地点：山东省淄博市张店区马尚街道办事处心环东路与荣二路 交汇处齐美大厦 27 层 3. 会议召开方式：现场投票与网络投票相结合 4. 会议召集人：公司董事会 5. 会议主持人：董事长岳家霖 通过现场和网络投票的股东 261 人，代表股份 171,628,127 股，占公司有表 决权股份总数 ...